Shamburg News · 8-K filed Nov 10, 2026, 4:22 PM EST

Palisade Bio Reports Third Quarter 2026 Financial Results and Clinical Program Updates

PALI · PALISADE BIO, INC.

  • Earnings
  • Financial statements
  • Materiality: high

Palisade Bio, Inc. reported financial results for the three and nine months ended September 30, 2026, in a press release dated November 10, 2026. For the third quarter, research and development expenses were $10.6 million and general and administrative expenses were $5.1 million, with a net loss of $14.6 million, or $0.07 per share. As of September 30, 2026, the Company had $113.6 million in cash and cash equivalents.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001357459-26-000025.

Written from the filing by Shamburg Markets. Figures are as reported by the company.